Hypertension (Dallas, Tex. : 1979) · 2026
Inhibition of ROCK2 via KD025/Belumosudil Alleviates Hypertensive End-Organ Damage.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fehrenbach Daniel J, Smart C Duncan, Wassenaar Jean W, Yasmin Sharia, Li Xinlan L, Sepulveda Marisa N, Imulinde Sugi Ariane, Shimokawa Hiroaki, Doran Amanda C, Kim Il-Man, Madhur Meena S
Аннотация
BACKGROUND: Despite achieving target blood pressure, hypertensive individuals have an elevated risk of cardiovascular disease, likely due to unresolved inflammation. Thus, adjunctive immune-modulating therapies are needed to protect patients with hypertension from end-organ damage. We previously showed that T helper 17 cells, which produce the proinflammatory cytokine IL (interleukin)-17A, contribute to hypertensive tissue injury. ROCK2 (Rho-associated coiled-coil-containing protein kinase 2) is a molecular switch governing T helper cell differentiation by promoting T helper 17 polarization and inhibiting T regulatory cell polarization. The present study tests whether T-cell-specific deletion of Rock2 or the Food and Drug Administration-approved ROCK2-specific inhibitor KD025/belumosudil protects against hypertension-associated end-organ damage.
METHODS: T-cell-specific Rock2 knockout mice (Rock2fl/flCD4Cre+) and Rock2fl/fl littermate controls were subjected to a 21-day deoxycorticosterone acetate-salt model of hypertension. In parallel, KD025/belumosudil treatment (50 mg/kg per day) starting after day 10 in wild-type mice was used to test the therapeutic potential of targeting ROCK2. Blood pressure, cardiac fibrosis, renal injury, and infiltration of immune cells were assessed.
RESULTS: T-cell-specific Rock2 deletion in mice attenuated the hypertensive response in the deoxycorticosterone acetate-salt model and protected from cardiac and aortic fibrosis. KD025/belumosudil treatment did not reduce blood pressure but did decrease proinflammatory T helper 17 polarization in vivo and increased the cardiac regulatory T cells/T helper 17 ratio. Despite no blood pressure change, KD025 reduced cardiac and aortic fibrosis, improved echocardiographic and invasive hemodynamic indices, and attenuated albuminuria and renal T-cell infiltration.
CONCLUSIONS: ROCK2 inhibition may serve as an adjunct immune-modulating therapy to mitigate the end-organ damage that occurs in the heart, vasculature, and kidney in hypertension.
METHODS: T-cell-specific Rock2 knockout mice (Rock2fl/flCD4Cre+) and Rock2fl/fl littermate controls were subjected to a 21-day deoxycorticosterone acetate-salt model of hypertension. In parallel, KD025/belumosudil treatment (50 mg/kg per day) starting after day 10 in wild-type mice was used to test the therapeutic potential of targeting ROCK2. Blood pressure, cardiac fibrosis, renal injury, and infiltration of immune cells were assessed.
RESULTS: T-cell-specific Rock2 deletion in mice attenuated the hypertensive response in the deoxycorticosterone acetate-salt model and protected from cardiac and aortic fibrosis. KD025/belumosudil treatment did not reduce blood pressure but did decrease proinflammatory T helper 17 polarization in vivo and increased the cardiac regulatory T cells/T helper 17 ratio. Despite no blood pressure change, KD025 reduced cardiac and aortic fibrosis, improved echocardiographic and invasive hemodynamic indices, and attenuated albuminuria and renal T-cell infiltration.
CONCLUSIONS: ROCK2 inhibition may serve as an adjunct immune-modulating therapy to mitigate the end-organ damage that occurs in the heart, vasculature, and kidney in hypertension.